| Drug Name |
Bezafibrate |
| Drug ID |
BADD_D00270 |
| Description |
Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins. |
| Indications and Usage |
For the treatment of primary hyperlipidaemia types IIa, IIb, III, IV and V (Fredrickson classification) corresponding to groups I, II and III of the European Atherosclerosis Society guidelines - when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. Also for the treatment of secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus). |
| Marketing Status |
approved; investigational |
| ATC Code |
C10AB02 |
| DrugBank ID |
DB01393
|
| KEGG ID |
D01366
|
| MeSH ID |
D001629
|
| PubChem ID |
39042
|
| TTD Drug ID |
D00WCX
|
| NDC Product Code |
17337-0094 |
| UNII |
Y9449Q51XH
|
| Synonyms |
Bezafibrate | Solibay | Eulitop | durabezur | Azufibrat | Befibrat | Beza-Lande | Beza Lande | Beza-Puren | Beza Puren | Bezabeta | Bezacur | Bezafibrat PB | Bezafisal | Bezalip | Bezamerck | BM-15.075 | BM 15.075 | BM15.075 | Cedur | Lipox | Reducterol | Regadrin B | Sklerofibrat | Béfizal | Difaterol |
